

Colartix® hydrolyzed cartilage matrix is patented by Rousselot in Europe, Japan, and China

02 September 2025 | News

Underscores innovation in the collagen industry; Joint health supplement market, hit \$4.4 billion in 2024 and is set to grow 2.4% annually through 2029



Rousselot, Darling Ingredients' health brand, has been granted patents in Europe, Japan and China for Colartix, its unique matrix of collagen peptides and chondroitin sulfate. Specifically designed for joint care, Colartix is now patented under the title *Collagen hydrolysate composition for reducing joint pain after exercise*.

Backed by scientific research demonstrating its efficacy in alleviating joint discomfort across gender, age and sport intensity, Colartix has gained strong market traction since its launch in 2022. Widely incorporated into dietary supplements, it supports both active individuals and those experiencing wear and tear due to aging or excess weight. This demand aligns with the joint health supplement market, which hit \$4.4 billion in 2024 and is set to grow 2.4% annually through 2029.

Colartix is a natural, safe and easy-to-use ingredient, delivering benefits with just 1 gram of daily intake. Its small daily dosage and ability to blend seamlessly with other ingredients make it ideal for a variety of applications, including capsules, powder supplements, tablets and shots.

The European patent, granted by the European Patent Office, is registered under the number EP4465823B1. The Japanese patent, issued by the Japan Patent Office, holds the number JP7690140B2. The Chinese patent, granted by the China National Intellectual Property Administration, is registered under number CN118829360. Patent applications for Colartix are also pending in Brazil and the United States.